Hangzhou Tigermed Consulting Co. Ltd
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and to… Read more
Hangzhou Tigermed Consulting Co. Ltd (HNGZY) - Total Assets
Latest total assets as of September 2025: $28.79 Billion USD
Based on the latest financial reports, Hangzhou Tigermed Consulting Co. Ltd (HNGZY) holds total assets worth $28.79 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hangzhou Tigermed Consulting Co. Ltd - Total Assets Trend (2009–2024)
This chart illustrates how Hangzhou Tigermed Consulting Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hangzhou Tigermed Consulting Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Hangzhou Tigermed Consulting Co. Ltd's total assets of $28.79 Billion consist of 22.0% current assets and 78.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.2% |
| Accounts Receivable | $3.96 Billion | 13.8% |
| Inventory | $31.96 Million | 0.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $336.88 Million | 1.2% |
| Goodwill | $3.23 Billion | 11.3% |
Asset Composition Trend (2009–2024)
This chart illustrates how Hangzhou Tigermed Consulting Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hangzhou Tigermed Consulting Co. Ltd's current assets represent 22.0% of total assets in 2024, a decrease from 55.8% in 2009.
- Cash Position: Cash and equivalents constituted 7.2% of total assets in 2024, down from 25.9% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, a decrease from 17.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 13.8% of total assets.
Hangzhou Tigermed Consulting Co. Ltd Competitors by Total Assets
Key competitors of Hangzhou Tigermed Consulting Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Hangzhou Tigermed Consulting Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hangzhou Tigermed Consulting Co. Ltd generates 0.23x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Hangzhou Tigermed Consulting Co. Ltd generates $ 1.41 in net profit.
Hangzhou Tigermed Consulting Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.16 | 1.37 | 10.22 |
| Quick Ratio | 2.15 | 1.36 | 10.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.41 Billion | $ 1.75 Billion | $ 10.51 Billion |
Hangzhou Tigermed Consulting Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Hangzhou Tigermed Consulting Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.22 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -3.4% |
| Total Assets | $28.67 Billion |
| Market Capitalization | $2.55 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hangzhou Tigermed Consulting Co. Ltd's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Hangzhou Tigermed Consulting Co. Ltd's assets decreased by 3.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Hangzhou Tigermed Consulting Co. Ltd (2009–2024)
The table below shows the annual total assets of Hangzhou Tigermed Consulting Co. Ltd from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $28.67 Billion | -3.40% |
| 2023-12-31 | $29.68 Billion | +8.14% |
| 2022-12-31 | $27.45 Billion | +15.61% |
| 2021-12-31 | $23.74 Billion | +21.71% |
| 2020-12-31 | $19.51 Billion | +158.95% |
| 2019-12-31 | $7.53 Billion | +76.01% |
| 2018-12-31 | $4.28 Billion | +19.44% |
| 2017-12-31 | $3.58 Billion | +50.03% |
| 2016-12-31 | $2.39 Billion | +48.34% |
| 2015-12-31 | $1.61 Billion | +18.59% |
| 2014-12-31 | $1.36 Billion | +68.02% |
| 2013-12-31 | $808.01 Million | +10.26% |
| 2012-12-31 | $732.84 Million | +292.40% |
| 2011-12-31 | $186.76 Million | +55.75% |
| 2010-12-31 | $119.91 Million | +77.94% |
| 2009-12-31 | $67.39 Million | -- |